Ashton Thomas Private Wealth LLC Acquires New Stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Ashton Thomas Private Wealth LLC bought a new position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the second quarter, Holdings Channel.com reports. The fund bought 400 shares of the company’s stock, valued at approximately $26,000.

A number of other institutional investors have also recently added to or reduced their stakes in PBE. GPS Wealth Strategies Group LLC bought a new stake in Invesco Biotechnology & Genome ETF during the second quarter worth approximately $30,000. UMB Bank n.a. acquired a new position in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth $31,000. Covestor Ltd raised its position in shares of Invesco Biotechnology & Genome ETF by 24.2% during the first quarter. Covestor Ltd now owns 955 shares of the company’s stock worth $62,000 after purchasing an additional 186 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the first quarter valued at $232,000. Finally, Cetera Advisors LLC acquired a new position in shares of Invesco Biotechnology & Genome ETF in the 1st quarter valued at $328,000.

Invesco Biotechnology & Genome ETF Trading Up 0.0 %

Shares of PBE opened at $71.25 on Wednesday. The business’s 50-day moving average price is $69.65 and its 200 day moving average price is $65.89. The stock has a market capitalization of $287.85 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1-year low of $52.47 and a 1-year high of $72.72.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.